Inhibitory activities of kukoamines A and B from Lycii Cortex on amyloid aggregation related to Alzheimer’s disease and type 2 diabetes

Journal of Natural Medicines volume 74, pages247–251(2020)Cite this article

Abstract

Alzheimer’s diseases (AD) and type 2 diabetes (T2D) are two age-related diseases characterized by amyloid fibrillogenesis. Prevention of amyloid aggregation is a promising therapeutic strategy for AD and T2D. Two spermine alkaloids, kukoamines A and B, isolated from Lycii Cortex (LyC) were investigated for their inhibitory effect on amyloid aggregation. Both kukoamines A and B inhibited aggregation of amyloid β (Aβ) and human islet amyloid polypeptide (hIAPP) in a dose-dependent manner. Kukoamine B showed stronger inhibitory activity than kukoamine A. These results on the inhibitory activity of kukoamines A and B on Aβ and hIAPP indicate that the catechol moiety is essential for inhibition of amyloid aggregation.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53:474–481

    CAS  Article  Google Scholar 

  2. 2.

    Flier JS (2004) Obesity wars: molecular progress confronts an expanding epidemic. Cell 116:337–350

    CAS  Article  Google Scholar 

  3. 3.

    Maher PA, Schubert DR (2009) Metabolic links between diabetes and Alzheimer’s disease. Expert Rev Neurother 9:617–630

    CAS  Article  Google Scholar 

  4. 4.

    Alzheimer’s Association (2010) Alzheimer’s disease facts and figures. Alzheimers Dement 6:158–194

    Article  Google Scholar 

  5. 5.

    Alzheimer’s Association (2013) Alzheimer’s disease facts and figures. Alzheimers Dement 9:208–245

    Article  Google Scholar 

  6. 6.

    Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:42–45

    Article  Google Scholar 

  7. 7.

    Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885–890

    CAS  Article  Google Scholar 

  8. 8.

    Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628–8632

    CAS  Article  Google Scholar 

  9. 9.

    Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84:3881–3885

    CAS  Article  Google Scholar 

  10. 10.

    Johnson KH, O’Brien TD, Hayden DW, Jordan K, Ghobrial HK, Mahoney WC, Westermark P (1988) Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J Pathol 130:1–8

    CAS  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Andreetto E, Yan LM, Tatarek-Nossol M, Velkova A, Frank R, Kapurniotu A (2010) Identification of hot regions of the Aβ–IAPP interaction interface as high-affinity binding sites in both cross- and self-association. Angew Chem Int Ed Engl 49:3081–3085

    CAS  Article  Google Scholar 

  12. 12.

    Toyama BH, Weissman JS (2011) Amyloid structure: conformational diversity and consequences. Annu Rev Biochem 80:1–32

    Article  Google Scholar 

  13. 13.

    Kurochkin IV, Goto S (1994) Alzheimer’s beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345:33–37

    CAS  Article  Google Scholar 

  14. 14.

    Miyamae Y, Kurisu M, Murakami K, Han J, Isoda H, Irie K, Shigemori H (2012) Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid β-protein. Bioorg Med Chem 20:5844–5849

    CAS  Article  Google Scholar 

  15. 15.

    Kurisu M, Miyamae Y, Murakami K, Han J, Isoda H, Irie K, Shigemori H (2013) Inhibition of amyloid β aggregation by acteoside, a phenylethanoid glycoside. Biosci Biotech Biochem 77:1329–1332

    CAS  Article  Google Scholar 

  16. 16.

    Kidachi E, Kurisu M, Miyamae Y, Hanaki M, Murakami K, Irie K, Shigemori H (2016) Structure-activity relationship of phenylethanoid glycosides on the inhibition of amyloid β aggregation. Heterocycles 92:1976–1982

    CAS  Article  Google Scholar 

  17. 17.

    Aihara Y, Kawaguchi A, Hanaki M, Murakami K, Irie K, Shigemori H (2017) Inhibitory activity of hispidin derivatives isolated from Inonotus obliquus on amyloid β aggregation. Heterocycles 94:1280–1287

    CAS  Article  Google Scholar 

  18. 18.

    Tsunoda T, Takase M, Shigemori H (2018) Structure-activity relationship of clovamide and its related compounds for the inhibition of amyloid β aggregation. Bioorg Med Chem 26:3202–3209

    CAS  Article  Google Scholar 

  19. 19.

    Hmidene AB, Hanaki M, Murakami K, Irie K, Isoda H, Shigemori H (2017) Inhibitory activities of antioxidant flavonoids from Tamarix gallica on amyloid aggregation related to Alzheimer’s and type 2 diabetes diseases. Biol Pharm Bull 40:238–241

    Article  Google Scholar 

  20. 20.

    Ye Z, Huang Q, Ni HX, Wang D (2008) Cortex Lycii Radicis extracts improve insulin resistance and lipid metabolism in obese-diabetic rats. Phytother Res 22:1665–1670

    Article  Google Scholar 

  21. 21.

    Yao X, Peng Y, Xu LJ, Li L, Wu QL, Xiao PG (2011) Phyto-chemical and biological studies of Lycium medicinal plants. Chem Bio Divers 8:976–1010

    CAS  Google Scholar 

  22. 22.

    Hu XL, Gao LY, Niu YX, Tian X, Wang J, Meng WH, Zhang Q, Cui C, Han L, Zhao QC (2015) Neuroprotection by kukoamine A against oxidative stress may involve N-methyl-D-aspartate receptors. Biochim Biophys Acta 1850:287–298

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We are pleased to acknowledge Professor Kazuhiro Irie, Associate Professor Kazuma Murakami, and Dr. Mizuho Hanaki, Graduate School of Agriculture, Kyoto University for preparing Aβ42. We would like to thank Editage (www.editage.jp) for English language editing. This work was partially supported by JSPS KAKENHI grant no. JP24580156.

Author information

Affiliations

  1. Graduate School of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Ibaraki, 305-8572, Japan

    Gandan Jiang, Mio Takase & Yukine Aihara

  2. Faculty of Life and Environmental Sciences, University of Tsukuba, Tsukuba, Ibaraki, 305-8572, Japan

    Hideyuki Shigemori

Authors
  1. Gandan Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mio Takase
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yukine Aihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideyuki Shigemori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideyuki Shigemori.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jiang, G., Takase, M., Aihara, Y. et al. Inhibitory activities of kukoamines A and B from Lycii Cortex on amyloid aggregation related to Alzheimer’s disease and type 2 diabetes. J Nat Med 74, 247–251 (2020). https://doi.org/10.1007/s11418-019-01337-0

Download citation

Keywords

  • Kukoamines A and B
  • Lycii Cortex
  • Amyloid aggregation
  • Alzheimer’s disease
  • Type 2 diabetes